Lakewood-Amedex Biotherapeutics

LABT

Börsenwert 1,37 Mio. $

Intravesical administration of the Bisphosphocin ® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E.

SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D.

Lead candidate Nu-3 is a topically formulated Bisphosphocin ® , designed to rapidly kill microbes while reducing the risk of antimicrobial resistance SARASOTA, Fla., Sept. 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced positive Minimum Inhibitory Concentration (MIC) data from recent clinical isolates for its lead clinical candidate, Nu-3.

Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin ® antimicrobial platform Topline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of patients with mildly infected diabetic foot ulcers (iDFU).

Clinical and Corporate Highlights Successfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company's evolution Strengthened balance sheet through completion of a $7.5 million private placement to support continued clinical advancement Reported positive preclinical safety and tolerability data supporting dose selection for the upcoming Phase 2a clinical trial evaluating Nu-3 Gel in infected diabetic foot ulcers (iDFUs) Announced internationally recognized diabetic foot expert David G. Armstrong, DPM, MD, Ph.D.

SARASOTA, Fla., Sept. 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial evaluating the safety and efficacy of its lead product candidate, Nu-3, in patients with mildly infected diabetic foot ulcers (iDFU).

SARASOTA, Fla., Sept. 8, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D.

Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance. SARASOTA, Fla.

Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects. SARASOTA, Fla.

Company highlights its differentiated Bisphosphocin ® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance development SARASOTA, Fla., July 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, legislation designed to encourage the development of novel therapies to address the growing global threat of antimicrobial resistance (AMR).